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Abstract
 
Murine natural killer cells (NK) express lectin-like activation and inhibitory receptors, includ-
ing the CD94/NKG2 family of receptors that bind Qa-1, and the Ly-49 family that recog-
nizes major histocompatibility complex class I molecules. Here, we demonstrate that cross-
linking of NK cells with a new specific anti–Ly-49H mAb induced NK cell cytotoxicity and
cytokine production. Ly-49H is expressed on a subset of NK cells and can be coexpressed
with Ly-49 inhibitory receptors. However, unlike Ly-49 inhibitory receptors, Ly-49H is not
 
detectable on naive splenic CD3
 
1
 
 T cells, indicating that Ly-49H may be an NK cell–specific
activation receptor. In further contrast to the stochastically expressed Ly-49 inhibitory recep-
tors, Ly-49H is preferentially expressed with the Ly-49D activation receptor, and expression
of both Ly-49H and Ly-49D is augmented on NK cells that lack receptors for Qa-1 tetramers.
On developing splenic NK1.1
 
1
 
 cells, Ly-49D and Ly-49H are expressed later than the inhib-
itory receptors. These results directly demonstrate that Ly-49H activates primary NK cells,
and suggest that expression of Ly-49 activation receptors by NK cells may be specifically reg-
ulated on NK cell subsets. The simultaneous expression of multiple activation receptors by in-
dividual NK cells contrasts with that of T cell antigen receptors and is relevant to the role of
NK cells in innate immunity.
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Introduction
 
NK cells lyse tumor or virally infected cells without prior
sensitization in a process known as natural killing (1, 2).
This process results in the exocytosis of granules contain-
ing perforin and granzymes that mediate target apoptosis.
Upon exposure to their cellular targets, NK cells also pro-
 
duce cytokines such as IFN-
 
g
 
, GM-CSF, and TNF-
 
a
 
 (3).
Recently, significant strides have been made to explain
how NK cells recognize their targets to initiate these effec-
tor functions. One current model suggests that NK cells
 
express two types of
 
 
 
receptors, an activation type receptor
and a second inhibitory receptor that binds MHC class I
molecules and inhibits NK cell activation (4, 5). This
model is consistent with the missing-self hypothesis postu-
lating that NK cells survey tissues for normal expression of
MHC class I and can be released to kill in the absence of
MHC class I (6).
Over the last few years, major advances have elucidated
the structure and function of the MHC class I inhibitory
receptors (7–9). These receptors fall into two structural
categories. NK cells express type I integral membrane, Ig-
like receptors, such as the killer cell Ig-like receptors
(KIRs) on human NK cells, and gp49B on mouse NK
cells (10–12). These molecules are usually expressed as
monomeric receptors. On the other hand, NK cells also
express type II integral membrane, C-type lectin-like di-
sulfide-linked dimeric proteins such as the homodimeric
Ly-49A receptor on mouse NK cells, and the CD94/
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NKG2A heterodimer on human and mouse NK cells (13–
17). Despite these structural differences, all inhibitory re-
ceptors appear to mediate their functional effects through
the same mechanism involving ligand-induced tyrosine
phosphorylation of cytoplasmic sequences, termed immu-
noreceptor tyrosine-based inhibitory motifs (ITIMs)
 
1
 
 (8).
Phosphorylated ITIMs then recruit tyrosine phosphatases,
such as SH2 domain–bearing protein tyrosine phosphatase
(SHP-1), that presumably dephosphorylate molecules in
the activation cascade.
Much less is known about the nature of putative NK
cell activation receptors. Whereas NK cells express Fc
 
g
 
-
RIII (CD16) that mediates antibody-dependent cellular
cytotoxicity (18), CD16 appears not to be directly respon-
sible for most instances of NK cell activation by targets (5).
Instead, leading candidates for target-specific NK cell acti-
vation receptors are molecules that are homologous to
both structural types of inhibitory receptors but do not
contain cytoplasmic ITIMs (5). These NK cell molecules
also contain charged residues in their transmembrane do-
mains that facilitate interaction with associated immunore-
ceptor tyrosine-based activation motif (ITAM)-containing
signaling chains such as DAP-12 and Fc
 
e
 
RI
 
g
 
 (19, 20). As
such, human killer activation receptors have been de-
scribed that are homologous to the inhibitory killer cell
Ig-like receptors (KIRs) and can costimulate NK cell acti-
vation when cross-linked by mAbs or exposure to target
ligands (21, 22).
The C-type lectin-like receptors NKR-P1, CD94/
NKG2C, Ly-49D, and Ly-49H have also been implicated
in activating NK cells (20, 23–28). Although NKR-P1 ap-
pears to be expressed on all murine NK cells, it is not clear
whether the additional lectin-like receptors can be ex-
pressed together on the same cell or whether expression of
these molecules is regulated in some way that excludes or
modifies coexpression. Whereas the ligands for NKR-P1
molecules are not clearly understood, cross-linking of rat
NKR-P1 or mouse NKR-P1C (equivalent to the NK1.1
antigen) stimulates NK cell activation (29, 30). The hu-
man inhibitory CD94/NKG2A and activation CD94/
NKG2C heterodimeric receptors recognize HLA-E li-
gands, and orthologues of these receptors recognize Qa-1
in mice (31, 32). As yet, the function of the CD94/
NKG2C activation receptor has not been well studied on
primary NK cells, although transfection and cross-linking
of chimeric molecules containing the transmembrane and
cytoplasmic domain of CD94/NKG2C can activate NK
tumor cells (27). mAb cross-linking of Ly-49D on sorted
NK cells as well as on transfected cell lines can induce lysis
of target cells (28). Furthermore, Ly-49D is responsible for
directly activating mouse NK cells to kill Chinese hamster
ovary (CHO) cells, presumably by recognition of a target
ligand, and Ly-49D specifically recognizes the MHC class
 
I molecule H-2D
 
d
 
 on mouse targets (33, 34). However,
much less is known about the properties of the Ly-49H
molecule.
The Ly-49H cDNA was first identified by Takei and co-
workers as a member of the Ly-49 multigene family, which
now encompasses cDNAs or genes encoding the Ly-49A
through Ly-49J molecules (35, 36). Like Ly-49A, most
members of the Ly-49 family have ITIMs and several are
known to have functions as MHC class I–specific inhibi-
tory receptors (37). Use of serological reagents specific for
certain Ly-49 family members has shown that Ly-49 family
members are expressed in C57BL/6 (B6) mice by subsets of
NK1.1
 
1
 
CD3
 
–
 
 NK cells and NK1.1
 
1
 
CD3
 
1
 
 cells, i.e., NKT
cells (13, 38). Many of these cells express more than one
Ly-49 molecule. By contrast, and with marked similarity to
Ly-49D, Ly-49H lacks a cytoplasmic ITIM and contains a
charged residue (arginine) in the transmembrane domain,
suggesting an activating function. In support of this role,
myc-tagged Ly-49H was shown to associate with DAP-12
in transfected Ba/F3 cells and to initiate early events in cel-
lular activation after cross-linking with anti-myc antibody
(39). However, the role of Ly-49H on primary NK cells
remains to be established. It is not clear which NK cell ef-
fector functions Ly-49H could potentially activate or regu-
late, or whether stimulation through Ly-49H alone is suffi-
cient to initiate NK cell activation. Moreover, although
Ly-49H is related to the Ly-49D activation receptor and
both can couple to DAP-12, it has not been determined if
these two Ly-49 molecules mediate similar functions on
NK cells. Finally, it is not known if NK cells can simulta-
neously express both Ly-49D and Ly-49H or if these mol-
ecules can be coexpressed with other lectin-like receptors
such as the CD94/NKG2 family of molecules.
Detailed analyses of the serologically detectable inhibi-
tory Ly-49 molecules (Ly-49A, Ly-49C/I, and Ly-49G)
have demonstrated that each of these molecules is expressed
in a developmentally regulated manner (40). These recep-
tors are detectable on a small fraction of murine NK cells in
the spleen 1–2 d after birth. Over the next 4–6 wk, NK
cells expressing these receptors gradually increase to adult
percentages, at which point mature NK cells can express
more than one Ly-49 molecule. This coexpression of Ly-
49 inhibitory molecules on a single cell appears to be due
to a stochastic rather than an ordered process when ana-
lyzed by the multiplication rule for independent probabili-
ties (37). That is, the percentage of NK cells expressing two
distinct inhibitory Ly-49 molecules can be readily pre-
dicted from the product of their frequencies in the total
NK cell population. These observations strongly suggest
that expression of Ly-49 inhibitory receptors on NK cells is
a stochastic process. However, it is not yet known if Ly-49
activation receptors are expressed by a similar mechanism.
In this report, we used a new Ly-49H–specific mAb to
evaluate Ly-49H function on primary NK cells and ex-
plore its expression. These studies demonstrate that Ly-
49H can directly activate primary NK cells, and that NK
cells are heterogeneous with respect to expression of acti-
vation receptors. Unlike the inhibitory Ly-49 receptors,
 
1
 
Abbreviations used in this paper:
 
 B6, C57BL/6; CHO, chinese hamster
ovary; FCS, fetal calf serum; HRP, horseradish peroxidase; ITIM, im-
munoreceptor tyrosine-based inhibitory motif; NWNA, nylon wool
nonadherent. 
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Ly-49 activation receptors as well as receptors for tetra-
mers of the MHC class Ib Qa-1 molecule are expressed in
a nonstochastic and presumably developmentally regulated
manner on NK cells.
 
Materials and Methods
 
Mice.
 
B6 and BALB/c mice were purchased from National
Cancer Institute (Frederick, MD). All mice were housed in a
pathogen-free barrier facility at Washington University.
 
Cells and Cell Lines.
 
B cell hybridomas were grown in DMEM
containing 10% FCS obtained from Harlan, 2 mM glutamine, 100
U/ml penicillin, 100 
 
m
 
g/ml streptomycin, and 100 
 
m
 
M 2-ME at
37
 
8
 
C in 5% CO
 
2
 
. The murine H-2
 
b
 
 C1498 and EL-4 cell lines
were acquired from American Type Culture Collection and grown
in RPMI 1640 containing 10% FCS, 2 mM glutamine, 100 U/ml
penicillin, 100 
 
m
 
g/ml streptomycin, and 100 
 
m
 
M 2-ME. The
human 293T cell line, maintained in DMEM plus 10% FCS, was a
gift from Dr. John Vaage (University of Oslo, Oslo, Norway).
CHO-dhfr
 
2
 
 cells and the CHO-dhfr
 
2
 
 cell line stably expressing
Ly-49A were described previously (41). Unseparated splenocytes
and nylon wool nonadherent (NWNA) splenocytes were prepared
as described previously (30). Neonatal splenocytes were prepared
similarly, but were not passaged over nylon wool columns. For
IL-2–activated NK cell culture, NWNA splenocytes were cultured
in 1,000 U/ml recombinant human IL-2 (Chiron) at 5 
 
3
 
 10
 
5
 
 cells/
ml for 4 d. Plastic nonadherent cells were then discarded and ad-
herent cells were depleted of T cells by antibody H57-597 (anti–
TCR-
 
b
 
), mAb 53-6.72 (anti-CD4), and complement as described
(42). The remaining cells were cultured in 1,000 U/ml IL-2 for an
additional 4 d and harvested with EDTA (Versene; GIBCO BRL).
The resulting IL-2–activated NK cell population was routinely 95–
99% NK1.1
 
1
 
 and 
 
,
 
10% CD3
 
1
 
.
 
cDNAs, Expression Constructs, and Transfectants.
 
Ly-49B cDNA
was PCR amplified from reverse-transcribed B6 day 7 IL-2–acti-
vated NK cell mRNA with specific sense (5
 
9
 
-AGGCCA-
CATTTTAATACAAATCG-3
 
9
 
) and antisense (5
 
9
 
-CTGCTCT-
GTTAAGTCTGTTG-3
 
9
 
) primers as described previously (43)
and sequenced in both directions. The B6 Ly-49C cDNA in the
pAX142 expression vector and B6 Ly-49H cDNA in pBluescript
KS
 
2
 
 vector were gifts from Dr. Fumio Takei (University of Brit-
ish Columbia, Vancouver, Canada). The B6 Ly-49D, Ly-49E,
Ly-49F, and Ly-49G2 cDNAs were reported previously (43).
The B6 Ly-49I cDNA was a gift from Dr. Vinay Kumar (Univer-
sity of Texas Southwestern, Dallas, Texas). The Ly-49B and Ly-
49I cDNAs were expressed using vector pA-puro, provided by
Dr. Andrew Chan (Washington University, St. Louis). Ly-49E
cDNA was mutated in the 5
 
9
 
 untranslated region by PCR to
change a naturally occurring ATG at position 96 (43) to ATA.
The Ly-49 cDNAs were ligated into the pH
 
b
 
AP-r-1-neo vector
(44) that we modified to include an independent expression cas-
sette of dhfr cDNA under control of an SV40 promoter following
the method described in reference 41. The expressed sequence
tag encoding murine DAP-12 (EST 242315) was obtained from
Genome Systems, sequenced on both strands, and ligated into the
eukaryotic expression vector pME-T7, a gift of Dr. John Vaage.
The chimeric Ly-49A/H cDNA was created by excising the
NotI-PstI fragment of Ly-49H cDNA in pBluescript (35). This
fragment encodes the Ly-49H ectodomain beginning at amino
acid residue 88 (cysteine; numbering according to the sequence
of the Ly-49H isoform containing the alternatively spliced cyto-
plasmic amino acid residues VCS [45]) and deletes the mem-
 
brane-proximal 20 amino acids. This fragment was ligated to the
nucleotide 374 PstI site of the Ly-49A cDNA isolated from plas-
mid pA1.3 (46; see Fig. 1). The resulting chimeric Ly-49A/H
cDNA was sequenced on both strands and ligated into vector
pA-puro for eukaryotic expression.
Mammalian cells stably expressing Ly-49 molecules were gen-
erated using standard electroporation, Ca
 
3
 
(PO
 
4
 
)
 
2
 
 transfection, or
lipid-mediated transfection methods. CHO cells were transfected
with the pA-puro-Ly-49I expression vector together with a
pSV2-dhfr expression vector as a selectable marker (44). C1498
cells were transfected with Ly-49B, Ly-49E, or chimeric Ly-
49A/H expression plasmids (described above). CHO-dhfr
 
2
 
 cells
expressing Ly-49G2 were selected with methotrexate and main-
tained as described (41). Transient transfections of 293T cells
were carried out using lipofectamine (GIBCO BRL) according
to the manufacturer’s protocol. 48 h after transfection, cells were
harvested with Versene (GIBCO BRL) and analyzed by flow cy-
tometry or immunoprecipitation.
 
Production of Anti–Ly-49H mAb.
 
BALB/c mice were inocu-
lated intraperitoneally with 10
 
7
 
 B6-derived C1498–Ly-49A/H
transfected cells emulsified in TDM-MPL adjuvant (Ribi Immu-
nochemical) and boosted three times at 3-wk intervals. Splenic B
cell hybridomas were produced by the Washington University
Hybridoma Center from a single BALB/c mouse. Culture super-
natants from 
 
z
 
450 hybridomas were screened by flow cytometry
for antibody binding to a cell population containing a 1:1 ratio of
normal C1498 cells and C1498–Ly-49A/H cells mixed in the
same tube. Culture supernatants that specifically shifted only half
the cells in the mixture were presumed to contain antibody spe-
cific for the Ly-49A/H molecule, whereas culture supernatants
positively staining all cells in this mixture were assumed to con-
tain antibodies specific for other B6 strain alloantigens. Hybrid-
oma culture supernatants were also tested at the same time for
binding to day 7 IL-2–activated B6 NK cells. This screen resulted
in five independent hybridomas that were subcloned twice by
limiting dilution. Each of these clones stained an identical per-
centage of B6 NK cells (described below), and all were IgG1 iso-
type as determined by ELISA (Southern Biotechnology Associ-
ates). One clone, mAb 3D10, was selected for further analysis.
 
Other Antibodies.
 
Anti-CD3–Cychrome, FITC-4E5 (anti–
Ly-49D), FITC-5E6 (anti–Ly-49C/I), and PE–PK-136 (anti-NK1.1)
were purchased from PharMingen. Biotin-4D11 (anti–Ly-49G)
and biotin-JR9 (anti–Ly-49A) were produced from hybridomas
provided by Dr. John Ortaldo (National Cancer Institute, Freder-
ick, MD) and Dr. Jacques Roland (Pasteur Institute, Paris, France),
respectively. The 9E10 hybridoma (IgG1 anti–c-myc) was pro-
vided by Dr. Andrew Chan. Antibodies were purified from spent
cell-free culture supernatants by affinity purification on a protein
G–Sepharose or protein A–Sepharose column (Amersham Pharma-
cia Biotech) using standard methods.
Purified mAbs were biotinylated using 
 
N
 
-hydroxysuccinim-
ide-biotin (NHS-biotin; Pierce Chemical Co.) according to the
manufacturer’s instructions. FITC-3D10 was produced with
FITC-celite (FITC isomer 1; Calbiochem) as described (47).
To produce a rabbit anti–Ly-49A NH
 
2
 
 terminus antiserum, a
synthetic peptide encoding the first 15 amino acids of Ly-49A
with an added COOH-terminal cysteine (MSEQEVTYSMVRF-
HKC) was coupled to KLH by the maleimidobenzoyl-
 
N
 
-
hydroxysuccinimide method (47). Rabbit antisera to this immuno-
gen were raised by Antibodies Incorporated according to standard
protocols. Antiserum 1298 binds the Ly-49A NH
 
2
 
 terminus and
cross-reacts with the NH
 
2
 
 termini of Ly-49B, C, D, E, G, H, and I
by immunoprecipitation analysis (data not shown). 
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Cell Surface Biotinylation and Immunoprecipitations.
 
Cell sur-
face biotinylation, cell lysis, and immunoprecipitation were car-
ried out essentially as described (47). Lysates were stored at
 
2
 
70
 
8
 
C if not used immediately. For immunoprecipitations, 1–2
 
m
 
l of antiserum 1298 or 5 
 
m
 
g of purified mAb was added to a
volume of lysate equivalent to 2 
 
3
 
 10
 
6
 
 cells with 20 
 
m
 
l of a 50%
slurry of protein A–Sepharose (Amersham Pharmacia Biotech).
mAb 9E10 (IgG1, anti–c-myc) was used as a control for mAb
3D10 (also IgG1). 5 
 
m
 
g of purified rabbit anti–mouse antibody
(Caltag) was included in immunoprecipitations with these IgG1
mAbs to increase binding to protein A–Sepharose. Immunopre-
cipitates were washed three times in lysis buffer, separated by
SDS-PAGE, and transferred to solid membrane (Immobilon;
Millipore). Blots were blocked in TBS-T (20 mM Tris, 0.9% wt/
vol NaCl, 0.05% Tween 20, pH 7.4) containing 1% BSA and
washed in TBS-T alone. Biotinylated proteins were visualized
with avidin–horseradish peroxidase (HRP) conjugate and en-
hanced chemiluminescence detection reagents (Amersham Phar-
macia Biotech) and photographic film (XK-1; Eastman Kodak
Co.).
 
Redirected Lysis Assay.
 
The redirected lysis assay using 
 
51
 
Cr-
labeled human Daudi B cell lymphoma targets was carried out as
described (30). Purified antibodies were used at a final concentra-
tion of 
 
z
 
2 
 
m
 
g/ml and were added to wells containing target cells
immediately before adding effector cells. Percent specific lysis was
calculated as described previously (30).
 
Cytokine Production Assay.
 
Stimulation of IL-2–activated NK
cells was performed essentially as described (3). 96-well flat-bot-
tomed tissue culture plates (Falcon; Becton Dickinson) were
coated with goat anti–mouse F(ab
 
9
 
)
 
2
 
 antibody at 10 
 
m
 
g/ml for
 
z
 
15 h at room temperature, washed three times, and blocked
with 2% BSA in PBS. Triplicate wells were then incubated with
anti–Ly-49H mAb, PK136 (anti-NK1.1) positive control mAb,
or isotype control mAb 9E10 at 10 
 
m
 
g/ml for 4–8 h, and washed
three times. 10
 
5
 
 IL-2–activated NK cells were plated in each well
and incubated at 37
 
8
 
C for 8 h. Culture supernatants were har-
vested and assayed for GM-CSF and IFN-
 
g
 
 by ELISA (En-
dogen). In each experiment, ELISA standard curves were derived
using recombinant cytokines, permitting quantitation of cytokine
concentrations.
 
Generation of Qa-1
 
b
 
 Tetramers.
 
The bacterial strain expressing
the mouse 
 
b
 
2-microglobulin gene was supplied by Dr. David
Margulies (National Institutes of Health, Bethesda, MD). Bacteria
expressing Qa-1
 
b
 
 was provided by M. Salcedo. Soluble MHC
complexes were produced as described previously (48, 49). In
brief, after isopropyl-
 
b
 
-
 
d
 
-thiogalactopyranoside (IPTG) induc-
tion of the bacteria, inclusion bodies were isolated and dissolved
in urea. Refolding in vitro was around a Qdm peptide
(AMAPRTLLL) synthesized by Macromolecular Resources (Fort
Collins, CO). After FPLC purification on a Superdex 75 column
(Amersham Pharmacia Biotech), complexes were enzymatically
biotinylated using BirA enzyme (Avidity). Free biotin was re-
moved using a monoQ column (Amersham Pharmacia Biotech),
and tetramerized with streptavidin-PE (PharMingen) at a 4:1 mo-
lar ratio.
 
Flow Cytometric Analysis.
 
Adherent cells from IL-2–activated
NK cell cultures were harvested with Versene (GIBCO BRL),
and washed three times in FACS
 
®
 
 buffer (HBSS without phenol
red, 3% FCS, 0.1% wt/vol NaN
 
3
 
). To block nonspecific Fc re-
ceptor binding, IL-2–activated NK cells and B6 splenocytes were
first incubated with mAb 2.4G2 (50) at 5 
 
m
 
g/ml in FACS
 
®
 
 buffer
for 15 min before addition of antibodies. For antibody staining,
5 
 
3
 
 10
 
5
 
 cells were incubated with antibodies at 1–5 
 
m
 
g/ml in 96-
 
well V-bottomed plates (Nalge Nunc International) for 30 min
on ice, then washed three times. Secondary reagents avidin-PE,
avidin-Cychrome, and avidin-allophycocyanin (PharMingen)
were used at optimum final concentrations as determined by ti-
tration experiments. During flow cytometry, cells were gated ac-
cording to forward and side scatter and cell surface marker ex-
pression (as indicated in the text). Where indicated, dead cells
were excluded by gating with propidium iodide staining (47).
Fluorescence data from 10
 
4
 
 to 10
 
5
 
 gated events were collected.
 
Statistical Analysis of Ly-49 Receptors on B6 NK Cells.
 
B6
NWNA splenocytes were analyzed by four-color flow cytome-
try. At least 10
 
4
 
 gated NK1.1
 
1
 
CD3
 
2
 
 cells were analyzed for ex-
pression of Ly-49H and a second Ly-49 molecule (as indicated in
each figure). For example, Ly-49H
 
1
 
A
 
1
 
, Ly-49H
 
1
 
A
 
2
 
, Ly-
49H
 
2
 
A
 
1
 
, and Ly-49H
 
2
 
A
 
2
 
 cell populations were determined and
association of Ly-49H with Ly-49A was analyzed by the 
 
x
 
2
 
 test of
independence.
 
Results
 
Generation of a Cell Line Stably Expressing Chimeric Ly-
49A/H Protein.
 
The Ly-49H cDNA predicts a charged
residue in the deduced transmembrane domain, suggesting
that efficient cell surface expression of Ly-49H requires as-
sociation with additional molecules such as DAP-12, as de-
scribed by Lanier and colleagues during the progress of this
work (19). To express the extracellular domain of B6 Ly-
49H in the absence of any associated molecules, we ex-
ploited the fact that the related Ly-49A molecule can be
readily expressed at the cell surface. We therefore created a
chimeric Ly-49A/H cDNA encoding the cytoplasmic,
transmembrane, and first 19 extracellular amino acids of
Ly-49A fused to the ectodomain of the B6 allotype of Ly-
49H beginning in the predicted Ly-49H stalk region at
amino acid residue 88 (Fig. 1 A, and Materials and Meth-
ods). This chimeric Ly-49A/H cDNA was placed under
control of the chicken b-actin promoter and stably ex-
pressed in the murine C1498 cell line. To evaluate expres-
sion of the Ly-49A/H molecule, lysates from cell surface
biotinylated C1498–Ly-49A/H cells were immunoprecipi-
tated with rabbit polyclonal anti–Ly-49A NH2 terminus
peptide antiserum 1298, and immunoprecipitates were vi-
sualized on Western blots with avidin-HRP conjugate
(Fig. 1 B). A biotinylated protein band migrating at 85 kD
under nonreducing SDS-PAGE was immunoprecipitated
from Ly-49A/H transfected cell lysates but not in the ab-
sence of antiserum or from untransfected C1498 cells. Un-
der reducing conditions, this band migrated at 45 kD, con-
sistent with the expression of the Ly-49A/H molecule as a
disulfide-linked homodimer. Similar detection and migra-
tion of Ly-49A protein immunoprecipitated from control
EL-4 cell lysates by antiserum 1298 confirmed the antise-
rum specificity and reducing conditions. A 27-kD protein
also detected in this analysis under reducing conditions was
nonspecific because it was present in lysates of both C1498
and C1498–Ly-49A/H cells, as well as in mock immuno-
precipitations from C1498–Ly-49A/H lysates (Fig. 1 B,
lane 2). These results indicated that the Ly-49A/H mole-
cule is expressed as a stable, disulfide-linked cell surface ho-1345 Smith et al.
modimer, consistent with the structure of native Ly-49
molecules.
Specificity of mAb 3D10. The C1498–Ly-49A/H trans-
fectant was used as an immunogen to produce BALB/c
anti–Ly-49H mAbs, resulting in the generation of candi-
date mAb 3D10. The specificity of mAb 3D10 for Ly-49
molecules was evaluated by flow cytometric or immuno-
precipitation analysis of a panel of cell lines transfected with
cDNAs for the B6-derived Ly-49A, B, C, D, E, G2, H, or
I molecules. Expression of transfected Ly-49 molecules for
which specific antibody was available was confirmed by
flow cytometry. Since antibodies specific for Ly-49B and
Ly-49E are not available, expression of these transfected
molecules was demonstrated by immunoprecipitation with
the rabbit anti–Ly-49 NH2 terminus polyclonal antiserum
1298. In these analyses, we were unable to detect expres-
sion of Ly-49F protein with antiserum 1298 that recognizes
the identical NH2-terminal 14 amino acids (the peptide re-
gion against which the antibody was raised) as the deduced
Ly-49F peptide. Cloning of two independent Ly-49F cDNAs
and transfection analysis in three separate cell lines also
failed to result in surface expression. Although the Ly-49F
cDNA contains an open reading frame, it is not currently
clear whether the Ly-49F cDNA we reported previously
(43) encodes a mature Ly-49 molecule, requires additional
molecules for expression, or represents a pseudogene or
sterile transcript. Therefore, we evaluated the reactivity of
mAb 3D10 for all other detectable, known Ly-49 mole-
cules.
In flow cytometric analysis, mAb 3D10 specifically
stained the C1498–Ly-49A/H cell line and 293T cells tran-
siently expressing Ly-49H (Fig. 2), the latter demonstrating
that mAb 3D10 recognizes the full-length B6 Ly-49H mol-
ecule. mAb 3D10 was unreactive with transfectants express-
ing Ly-49A, C, D, and G2. Under conditions of very high
Ly-49I expression in transiently transfected cells, or high
concentrations of mAb 3D10 (50 mg/ml), we observed
weak cross-reactivity of mAb 3D10 for Ly-49I (data not
shown). However, CHO cells stably overexpressing Ly-49I
at levels greater than Ly-49I expression on B6 splenocytes
were unreactive with mAb 3D10 in flow cytometry under
conditions used for subsequent analyses (Fig. 2). Similarly,
no reactivity was detected to lysates from Ly-49B and Ly-
49E transfected cells in immunoprecipitation analysis (Fig.
3). Antiserum 1298 specifically immunoprecipitated protein
migrating at z75-kD from these Ly-49B and Ly-49E trans-
fected cell lysates as well as from Ly-49A–expressing control
Figure 1. Chimeric Ly-49A/H
is expressed as a disulfide-linked
dimer on the surface of stably
transfected cells. (A) Schematic
diagram of the chimeric type II
integral membrane Ly-49A/H
protein. The cytoplasmic, trans-
membrane, stalk regions, and the
putative carbohydrate recogni-
tion domain (CRD) are de-
picted. The amino acid sequence
at the junction is depicted be-
neath the cartoon. Numbers re-
fer to the amino acid position in
the indicated Ly-49 sequences.
(B) Immunoprecipitation analy-
sis of chimeric Ly-49A/H pro-
tein on C1498 Ly-49A/H trans-
fectants. The indicated cells
were surface biotinylated, lysed,
and immunoprecipitated with
rabbit polyclonal anti-Ly-49A
NH2 terminus antibody, and
protein A–Sepharose. Immuno-
precipitates were separated by
SDS-PAGE, transferred to nylon
membrane, and visualized after
Western transfer with avidin-HRP conjugate and enhanced chemilumi-
nescence (ECL). Upper gel, non-reducing conditions; lower gel, reduc-
ing conditions.
Figure 2. mAb 3D10 specifically binds Ly-49H and does not cross-
react with Ly-49A, C, D, G2, or I. Flow cytometric analysis was conducted
with cell lines transfected with cDNAs encoding the indicated Ly-49 mol-
ecules for binding to mAb 3D10. Expression of each transfected cDNA
was verified with control mAbs as indicated (left panels). Dead cells were
excluded from the analysis by propidium iodide. mAb 3D10 specifically
recognized cells expressing Ly-49H or the chimeric Ly-49A/H molecule,
and was unreactive with cells expressing Ly-49A, C, D, G2, or I (right
panels). For the Ly-49D and Ly-49H transfections, a cDNA expression
construct encoding the murine DAP-12 molecule was cotransfected.1346 Nonstochastic Coexpression of Activation Receptors on NK Cells
EL-4 cell lysates (Fig. 3), confirming expression of each of
these Ly-49 proteins. These results indicate that mAb 3D10
specifically recognizes Ly-49H and, under the conditions
used here, does not cross-react with any other known, ex-
pressible Ly-49 proteins.
Although mouse DAP-12 has been reported to be re-
quired for expression of Ly-49H at the cell surface (39), in
our analysis using 293T cell transient transfection assays,
cotransfection of mouse DAP-12 was not necessary for de-
tectable cell surface expression of Ly-49H by mAb 3D10
staining of Ly-49H transfected cells (data not shown).
However, cotransfection of mouse DAP-12 cDNA aug-
mented expression of Ly-49D and Ly-49H molecules ap-
proximately twofold in 293T cells and was therefore in-
cluded in the Ly-49H (and Ly-49D) transfection assays
presented here (Fig. 2). Taken together, these results indi-
cate that mAb 3D10 recognizes a mouse DAP-12–inde-
pendent epitope on Ly-49H.
To examine the expression of Ly-49H on primary NK
cells, mAb 3D10 was used in further immunoprecipitation
analysis of IL-2–activated NK cells (Fig. 4). mAb 3D10
specifically immunoprecipitated a protein species that mi-
grated as a single band at z110 kD under nonreducing
conditions. Upon reduction, this protein band shifted to a
single species migrating at z55 kD, suggesting that Ly-
49H is expressed as a disulfide-linked homodimer on the
surface of B6 IL-2–activated NK cells. This expression pat-
tern and quaternary structure are consistent with that ob-
served for all Ly-49 molecules examined to date (5). Inas-
much as only one molecular species was observed, these
data further suggest that mAb 3D10 is immunospecific for
Ly-49H.
Anti–Ly-49H Induces Redirected Lysis. We next exam-
ined the ability of the anti–Ly-49H mAb 3D10 to activate
primary NK cells to kill the human FcgR1 Daudi B lym-
phoma cell line in the redirected lysis assay (Fig. 5). mAb
3D10 specifically induced killing of Daudi cells in a dose-
dependent manner. By contrast, addition of control mAbs
A1 (anti–Ly-49A) or 9E10 (IgG1 isotype control) did not
increase specific lysis of Daudi target cells when compared
with medium alone. Interestingly, the addition of positive
Figure 3. Immunoprecipitation analysis of mAb 3D10 with lysates from
Ly-49B transfected cells and Ly-49E transfected cells. Cells were surface
labeled with biotin, lysed, and immunoprecipitated with anti–Ly-49A rab-
bit antiserum 1298 (lanes 1, 2, and 5), isotype control mAb (lanes 3 and 6),
or mAb 3D10 (lanes 4 and 7) as described in the legend to Fig. 1.
Figure 4. Ly-49H is expressed on NK cells as a disulfide-linked dimer.
Lysates from cell-surface biotinylated B6 IL-2–activated NK cells were
immunoprecipitated with the indicated antibodies as described in the leg-
end to Fig. 1. mAb 3D10 specifically immunoprecipitates a disulfide-
linked dimer that migrates at 110 kD under nonreducing conditions and
55 kD upon reduction.
Figure 5. Anti–Ly-49H mAb redirects lysis of human Daudi cells. B6
IL-2–activated NK cells were incubated for 4 h at 378C with 104 51Cr-
labeled target cells at E/T ratios of 2.7, 8.3, and 25 in the presence of the
antibodies indicated.1347 Smith et al.
control mAb PK136 (anti-NK1.1) augmented lysis of
Daudi cells in a manner similar to the addition of mAb
3D10, even though 3D101 cells constitute a subpopulation
of NK cells whereas NK1.1 is expressed on all NK cells
(see below and Discussion). These data show that cross-
linking of Ly-49H is sufficient to activate NK cell cytotox-
icity, demonstrating that Ly-49H is an NK cell activation
receptor on primary NK cells.
Direct Ly-49H Cross-Linking Activates Cytokine Produc-
tion. As a further test of the capacity of Ly-49H to acti-
vate functions of primary NK cells, we examined the effect
of cross-linking Ly-49H on the production of cytokines.
Plate-bound anti–Ly-49H augmented the production of
GM-CSF and IFN-g by IL-2–activated NK cells, similar to
the effect of anti-NK1.1 mAb (Fig. 6). The lower levels of
cytokines produced by Ly-49H cross-linking compared
with NK1.1 cross-linking are consistent with the expres-
sion of Ly-49H on a subpopulation of NK cells (see be-
low), whereas the NK1.1 molecule is expressed on .98%
of NK cells in this particular experiment (data not shown,
and see Discussion). The effect of plate-bound anti–Ly-
49H mAb was specific, as the amount of cytokines pro-
duced in cultures containing anti–Ly-49H mAb was also
markedly higher than in culture wells containing irrelevant
IgG1 control antibody. These results demonstrate that
cross-linking of Ly-49H can activate primary NK cells to
produce the cytokines GM-CSF and IFN-g.
Expression of Ly-49H on B6 NK Cells. Flow cytomet-
ric analysis using mAb 3D10 with freshly isolated unfrac-
tionated splenocytes indicated that approximately half of
NK1.11CD32 cells expressed Ly-49H (data not shown).
Similarly, NWNA splenocytes revealed that z56% of
NK1.11CD32cells were reactive (Fig. 7 A, top left; and
Table I). Expression of Ly-49A, Ly-49C/I, Ly-49D, and
Ly-49G on this population was consistent with previous
reports (Table I; reference 37). After 7 d of culture in IL-2,
the percentage of NK cells expressing Ly-49H was main-
tained at 52% (Fig. 7 A, top right; and Table I), demon-
strating that the total fraction of NK cells expressing Ly-
49H is stable under these culture conditions.
Ly-49H was not detectable on CD31 cells in freshly iso-
lated splenocytes (data not shown), in preparations of fresh
NWNA splenocytes, or in cultured IL-2–activated
NWNA cells that had not been depleted of CD31 cells
(Fig. 7 A, bottom left and right, respectively). Examination
of Ly-49D expression using the 4E5 mAb gave similar re-
Figure 6. Anti–Ly-49H induces cytokine production by B6 IL-2–acti-
vated NK cells. Plate-bound anti-NK1.1 (mAb PK136), anti–Ly-49H
(mAb 3D10), or isotype control mAb were used to stimulate IL-2–acti-
vated NK cells for 8 h in 96-well flat-bottomed plates. Culture superna-
tants were assayed by ELISA for levels of GM-CSF and IFN-g. Stimula-
tion of IL-2–activated NK cells by anti–Ly-49H mAb induces production
of GM-CSF (left) and IFN-g (right) by IL-2–activated NK cells. Positive
control anti-NK1.1 mAb also induces production of GM-CSF and IFN-g,
whereas minimal induction of cytokine expression was observed in wells
containing control mAb.
Figure 7. Flow cytometric analysis of Ly-49H expression. (A) Ly-49H vs. NK1.1 or CD3e expression on freshly isolated NWNA splenocytes (left
side) or CD32 IL-2–activated NK cells (right side) (the bottom right panel contains IL-2–activated NK cells that were not depleted of CD31 cells). (B)
Coexpression of Ly-49H with Ly-49A (mAb A1), Ly-49D (mAb 4E5), Ly-49C/I (mAb 5E6), and Ly-49G (mAb 4D11) on gated NK1.11CD32 freshly
isolated NWNA splenocytes. (C) Coexpression of Ly-49H with Ly-49A, D, C/I, and G on CD32 IL-2–activated NK cells. For each contour plot, the
percentage of cells in each quadrant is indicted in the appropriate quadrant.1348 Nonstochastic Coexpression of Activation Receptors on NK Cells
sults (data not shown), demonstrating that Ly-49D is also
absent on CD31 cells in these cultures. These observations
indicate that both Ly-49H and Ly-49D are NK cell–spe-
cific receptors, unlike the inhibitory Ly-49A, Ly-49C/I,
and Ly-49G receptors, which are also expressed on CD31
cells (usually NK1.11CD31) (51).
We also analyzed the coexpression of other Ly-49 family
members with Ly-49H on NK cells. Ly-49H is coexpressed
on the Ly-49A, Ly-49C/I, and Ly-49G inhibitory receptor
subsets on fresh NWNA CD32 spleen cells (Fig. 7 B, and
Table I). After 7 d of culture in IL-2, the coexpression of
Ly-49H with each of the serologically detectable Ly-49 re-
ceptors changed minimally (Fig. 7 C), further supporting
the conclusion that Ly-49H expression on NK cells is stable
after IL-2 activation. Furthermore, with respect to Ly-49
activation receptors, flow cytometric analysis of total Ly-
49D and Ly-49H expression on B6 NK1.11CD32 NWNA
cells using mAbs 3D10 (anti–Ly-49H) and 4E5 (anti–Ly-
49D) together indicated that 75% of cells express either Ly-
49D, Ly-49H, or both Ly-49 activation receptors (Table I).
Careful studies of the serologically detectable Ly-49 in-
hibitory receptors have previously shown that the percent-
age of NK cells expressing two Ly-49 inhibitory receptors
can be approximated by the product of the individual fre-
quencies of each receptor in the total NK cell population,
termed the product rule for independent events (37). A
parallel approach to this analysis is to separate total NK cells
into Ly-49H1 and Ly-49H2 subsets and measure the ex-
pression of a second Ly-49 molecule on each subset. This
approach also permits statistical analysis by the x2 test of in-
dependence. We analyzed gated NK1.11CD32 NWNA
splenocytes according to Ly-49H and Ly-49A expression,
generating a dot plot of four NK cell subsets that were
Ly-49H1A1, Ly-49H1A2, Ly-49H2A1, and Ly-49H2A2.
This analysis determined that Ly-49A is expressed on 23%
of Ly-49H1 cells and on 21% of Ly-49H2 cells, suggesting
that expression of Ly-49A is independent of Ly-49H on
NK cells (Table I), compatible with a stochastic model for
expression of Ly-49 inhibitory receptors.
On the other hand, when this method was applied to co-
expression of Ly-49C/I, Ly-49D, or Ly-49G with Ly-49H,
these molecules were expressed on a greater percentage of
Ly-49H1 cells than on Ly-49H2 cells (Table I). The Ly-
49C/I proteins were expressed on 62% of Ly-49H1 cells and
54% of Ly-49H2 cells, and Ly-49G was also expressed on
62% of Ly-49H1 cells and 50% of Ly-49H2 cells. Most strik-
ingly, Ly-49D was preferentially expressed on 68% of Ly-
49H1 cells, whereas only 40% of Ly-49H2 cells express Ly-
49D (Table I). Taken together, these data suggest that the
stochastic expression of Ly-49 inhibitory receptors also ap-
pears to apply to coexpression of Ly-49A and Ly-49H on NK
cells. By contrast, there were small but consistent increases in
the NK cell expression of the Ly-49C/I and Ly-49G proteins
with Ly-49H, and there was a marked increase in Ly-49D
expression on Ly-49H1 NK cells compared with Ly-49H2
NK cells, suggesting that control of Ly-49H (and Ly-49D)
expression may not be explained by a stochastic model.
Expression of Ly-49 Activation and Inhibitory Molecules with
Qa-1 Receptors. Receptors for the MHC class Ib molecule
Qa-1 on murine NK cells have previously been shown to
be members of the lectin-like NKG2/CD94 family (52).
Recombinant Qa-1 tetramers containing bound Qdm pep-
tide specifically bind the heterodimeric CD94/NKG2A,
CD94/NKG2C, and the CD94/NKG2E complexes (52).
Since we observed preferential coexpression of Ly-49 acti-
vation receptors on a subset of NK cells, we used tetramers
of Qa-1/Qdm peptide complexes to compare expression of
CD94/NKG2 molecules with Ly-49 activation and inhibi-
tory molecules. Flow cytometric analysis of each serologi-
cally detectable Ly-49 molecule with Qa-1 receptors on
Table I. Distribution of Ly-49 Molecules on NK Cells
Ly-49A Ly-49C/I Ly-49D Ly-49G Ly-49H
Total Ly-49D
and Ly-49H
%%%%% %
Splenic NK cells 22 6 0.1 57 6 3.8 57 6 1.1 57 6 2.4 56 6 2.1 75 6 1.7
IL-2–activated NK cells 27 6 0.5 35 6 3.3 59 6 1.6 57 6 2.7 52 6 0.2 NA
Ly-49H1 splenocytes 23 6 0.1 62 6 1.6 68 6 1.3 62 6 2.8 NA NA
Ly-49H2 splenocytes 21 6 0.9 54 6 2.5 40 6 0.3 50 6 2.5 NA NA
Qa-1 receptor1 IL-2–
activated NK cells 23 6 3.1 43 6 5.2 38 6 5.9 48 6 0.9 45 6 18 54 6 6.7
Qa-1 receptor2 IL-2–
activated NK cells 25 6 3.9 55 6 4.8 72 6 6.2 61 6 2.1 67 6 16* 87 6 3.5
Mean percentages 6 SD from three independent cell preparations and analyses of NK1.11CD32 NWNA splenocytes or day 7 NK1.11CD32 IL-2–
activated NK cells, as indicated. Differences between Ly-49H1 and Ly-49H2 NK cells are significant by x2 test of independence, P , 0.025. NA,
not applicable.
*In a single experiment, Ly-49H expression was lower than generally observed, but the average difference between Ly-49H expression on Qa-11
and Qa-12 cells was 22 6 3.8%.1349 Smith et al.
NK1.11CD32 IL-2–activated NK cells revealed Ly-49 ex-
pression on both Qa-1 receptor1 and Qa-1 receptor2 NK
cell subsets (Fig. 8, and Table I). Ly-49A appears to be
similarly distributed on both Qa-1 receptor1 and Qa-1
receptor2 NK cell subsets, whereas Ly-49C/I and Ly-49G
expression is moderately diminished on Qa-1 receptor1
cells compared with cells lacking expression of Qa-1 recep-
tors. Thus, Ly-49 A expression and Qa-1 receptor expres-
sion appear to be independent of each other, but expression
of Ly-49C/I and Ly-49G may be moderately influenced by
Qa-1 receptor expression or vice versa.
By contrast, the Ly-49D and Ly-49H activation mole-
cules are expressed on a markedly smaller fraction of the
Qa-1 receptor1 NK cell subset than the Qa-1 receptor2
subset (Fig. 8, and Table I). This preferential distribution
of Ly-49 activation receptors on Qa-1 receptor2 cells is
similar to the preferential coexpression of Ly-49D and Ly-
49H on an NK cell subset, indicating that NK cells may
undergo developmental steps that partially favor or segre-
gate certain NK cell receptor phenotypes.
Ly-49D and Ly-49H Expression on Developing NK1.11
Splenocytes. Given the observed coexpression of the Ly-
49D and Ly-49H activation molecules with inhibitory Ly-
49 molecules, we sought to determine how these mole-
cules are expressed in ontogeny on NK1.11 splenocytes
with respect to the inhibitory Ly-49A, C/I, and G mole-
cules. In flow cytometric analysis, Ly-49D and Ly-49H
were not detectable on day 17 fetal thymocytes or fetal
liver (data not shown). However, Ly-49D and Ly-49H
were detected on 2.6 and 1.4% of NK1.11 splenocytes, re-
spectively, on postnatal day 3, compared with 5.3% of
NK1.11 splenocytes observed to express the Ly-49G in-
hibitory receptor (Fig. 9), consistent with previous studies
of Ly-49G (40). The Ly-49D1 subset of NK1.11 cells was
consistently larger than the Ly-49H1 subset, particularly
from days 3–21 postpartum (Fig. 9). These observations
suggest that Ly-49D is expressed shortly before Ly-49H in
this interval of NK1.11 cell development in the spleen. In
addition, the Ly-49D and Ly-49H activation receptors
took longer to reach near-adult percentages on NK1.11
cells than the inhibitory receptors, especially in the first 21 d
postpartum (Fig. 9). After this point, the percentage of cells
expressing Ly-49D and Ly-49H continues to increase,
whereas the expression of the inhibitory receptors reaches
a plateau, resulting in a greater fraction of NK1.11 spleno-
cytes expressing Ly-49D or Ly-49H at day 50 postpartum
than any one of the inhibitory receptors studied. Taken to-
gether, these results suggest that Ly-49D and Ly-49H re-
ceptor expression on NK1.11 cells lags behind Ly-49G,
Figure 8. Flow cytometric analysis of Ly-49 activation and inhibitory
molecule expression with Qa-1 receptors on IL-2–activated NK cells.
Coexpression of tetrameric recombinant Qa-1 folded with Qdm peptide
with Ly-49A (mAb A1), Ly-49C/I (mAb 5E6), Ly-49G (mAb 4D11),
Ly-49D (mAb 4E5), Ly-49H (mAb 3D10), and both Ly-49D and Ly-
49H. For each contour plot, the percentage of cells in each quadrant is in-
dicated in the appropriate quadrant.
Figure 9. Development of Ly-49 activation and inhibitory receptor expression on NK1.11 splenocytes. Single cell suspensions of splenocytes were
stained with anti-NK1.1 (mAb PK136) and the indicated antibodies and analyzed by flow cytometry for expression of the Ly-49A, Ly-49C/I, Ly-49D,
Ly-49G, and Ly-49H molecules. Left, percentage of splenic NK1.11 cells expressing the indicated Ly-49 molecule as a function of time after birth.
Right, the same data set but plotted as the percentage of maximum expression observed for each Ly-49 molecule as a function of time after birth.1350 Nonstochastic Coexpression of Activation Receptors on NK Cells
Ly-49C/I, and Ly-49A inhibitory receptor expression in
the postpartum period.
Discussion
An activating role for the Ly-49H molecule had been
previously suggested by studies of Ba/F3 pro-B cell trans-
fectants in vitro, showing that an epitope-tagged Ly-49H
molecule could induce initial biochemical events associated
with cellular activation (39). By producing an mAb that
specifically binds the Ly-49H molecule and does not cross-
react with other Ly-49 family members, we have shown
directly that cross-linking of Ly-49H on B6 IL-2–activated
NK cells is sufficient to induce NK cell cytotoxicity and
production of the immunoregulatory cytokines IFN-g and
GM-CSF.
Other NK cell receptors, such as the CD16, NK1.1,
murine Ly-49D, and human KAR molecules, can induce
NK cell cytotoxicity or cytokine production, indicating
that NK cells may use multiple different receptors to
achieve an activated state (20, 25–28). The simultaneous
expression of multiple activation receptors by individual
NK cells is strikingly different from the expression of a sin-
gle rearranged TCR on an individual T cell that is exquis-
itely specific for cognate antigen in the context of MHC
molecules. NK cell expression of numerous different acti-
vation NK cell receptors, presumably specific for distinct
ligands, is probably relevant to the role of NK cells in early,
innate immunity (Fig. 10). Despite a smaller total popula-
tion than T lymphocytes, large numbers of NK cells need
to be triggered immediately without clonal expansion for
significant effector responses. This type of “amplification”
would be possible if many NK cells express the same recep-
tor and if an individual NK cell expresses multiple recep-
tors that could respond to different stimuli. By contrast, ac-
tivation and expansion of appropriate antigen-specific T
cell clones require several days. Hence, detailed under-
standing of NK cell receptors, such as Ly-49H, and their
ligands should provide physiological insight into the role of
NK cells in innate immunity.
Some of the structurally distinct NK cell activation re-
ceptors apparently transduce signals through the same sig-
naling chain. For example, both Ly-49D and Ly-49H can
transduce extracellular signals via DAP-12 (39). Since we
demonstrate that an individual NK cell can express both
Ly-49D and Ly-49H, the Ly-49D1H1 NK cell may be
triggered by the ligands for either Ly-49D or Ly-49H with
potentially similar outcomes. Importantly, under condi-
tions in which cross-linking of either Ly-49D or Ly-49H
alone is insufficient to activate an NK cell, it is conceivable
that simultaneous cross-linking of both receptors could
produce a synergistic effect resulting in NK cell activation.
The importance of this synergistic signaling hypothesis is
that a target cell could trigger an individual NK cell by ex-
pression of either high levels of a single ligand for any ex-
pressed NK cell receptor or low levels of ligands for multi-
ple NK cell receptors. Further analysis of these hypotheses
will permit detailed evaluation of NK cell function.
The observation that cross-linking of Ly-49H can acti-
vate NK cell cytotoxicity and cytokine production in vitro
suggests that NK cells may use the Ly-49H receptor to de-
tect infected or damaged cells in vivo, presumably by signal-
ing through the associated DAP-12 molecule. We observed
similar levels of cytotoxicity induced by cross-linking Ly-
49H compared with cross-linking NK1.1, whereas NK cells
stimulated through Ly-49H produced less IFN-g and GM-
CSF than NK1.1-stimulated cells. One explanation for
these differences is that in the redirected lysis assay, mAb
3D10 (IgG1 isotype) binds the human Daudi cell line FcRs
with higher affinity than PK136 (IgG2a isotype) (53), result-
ing in a more efficient induction of cytotoxicity. By con-
trast, stimulation of NK cells through NK1.1 and the associ-
ated FcR common g chain could be more effective at
inducing cytokine release than stimulation through DAP-
Figure 10. A model contrasting amplification of ef-
fector cell responses between T and NK cells. Expres-
sion of NK cell activation receptors on overlapping
subsets could increase the repertoire of activation re-
ceptors expressed by a single NK cell. In contrast to T
lymphocytes that require days to clonally expand anti-
gen-specific cells into an effective population, NK cells
respond to target cell ligands immediately. In the
model shown here, expression of NK cell activation
receptors on overlapping subsets could potentially in-
crease the range of ligands a single NK cell could rec-
ognize, thereby activating a larger fraction of the NK
cell population in response to ligand. If NK cell activa-
tion receptors were expressed exclusively of each
other, the number of NK cells that could respond to
target cell expression of ligands would be reduced.1351 Smith et al.
12–linked Ly-49H. It is also possible that in the cytokine as-
say, the different amounts of cytokines produced are due to
NK1.1 expression on essentially all cells compared with Ly-
49H expression on approximately half the NK cells. Finally,
our studies using antibody cross-linking of Ly-49H cannot
totally exclude inadvertent cross-linking of other molecules
such as CD16 in the cytokine production assay we carried
out. However, the specific induction of cytokine produc-
tion by addition of Ly-49H mAb but not by control mAb
indicates that even if Ly-49H synergizes with a second NK
cell receptor in this assay, Ly-49H nevertheless functions to
activate NK cells.
Our analysis of Ly-49 expression on NK cell subsets de-
scribes a wide range of NK cell phenotypes with respect to
Ly-49. The current understanding of NK cells does not
immediately suggest a unified mechanism responsible for
this diverse distribution. Previous studies of Ly-49 inhibi-
tory receptor expression on NK cell subsets have demon-
strated that expression of these molecules on the same NK
cell appears to be stochastic rather than a regulated process
(40). The data we present here demonstrate that the frac-
tion of Ly-49H1 NK cells expressing Ly-49A is essentially
the same as the fraction of Ly-49H2 NK cells expressing
Ly-49A, implying that Ly-49A expression is not influenced
by Ly-49H expression and vice versa. This relationship also
appears to occur between Ly-49A and expression of Qa-1
receptors. Therefore, these data suggest that the coexpres-
sion of Ly-49H with the Ly-49A inhibitory receptor and
the coexpression of Qa-1 receptors with Ly-49A are also
stochastic, consistent with previous studies of the Ly-49 in-
hibitory receptors (37).
By contrast, our observations of Ly-49H expression with
other Ly-49 receptors are not readily explained by a sto-
chastic mechanism. We observed a modest but consistent
augmentation of expression of the Ly-49C/I and Ly-49G
receptors on Ly-49H1 cells compared with Ly-49H2 cells.
This same increase in Ly-49C/I and Ly-49G expression
was evident on Qa-1 tetramer2 cells compared with Qa-1
tetramer1 cells. These differences in Ly-49C/I and Ly-49G
expression are statistically significant when analyzed by the
x2 test of independence. However, we favor the interpreta-
tion that these differences may not be biologically mean-
ingful in the functional activity of Ly-49H1 versus Ly-
49H2 NK cell subsets or Qa-1 tetramer1 and Qa-1
tetramer2 subsets. It is possible that these slight disparities
in Ly-49C/I and Ly-49G expression arise from the order in
which Ly-49 genes are transcribed during NK cell ontog-
eny, and do not necessarily reflect a later selection for spe-
cific Ly-49 inhibitory receptors to be coexpressed with Ly-
49H or in the absence of receptors for Qa-1.
A more pronounced difference was apparent in the dis-
tribution of the Ly-49D activation receptor with Ly-49H.
The expression of Ly-49D on 57% of NK1.11CD32 cells
and the observation that 68% of Ly-49H1 NK cells express
Ly-49D suggest a positive association between these two
activation receptors. Expression of Ly-49D on only 40% of
Ly-49H2 NK cells further implies that the lack of Ly-49H
expression on a cell correlates with the lack of Ly-49D ex-
pression. Similarly, both Ly-49D and Ly-49H expression
was augmented on NK cells that lacked expression of re-
ceptors for Qa-1. Furthermore, 87% of NK cells that did
not bind Qa-1 tetramers expressed either Ly-49D or Ly-
49H compared with 54% of NK cells that expressed re-
ceptors for Qa-1. These results indicate that a mechanism
exists in B6 mice that selects coexpression of Ly-49D and
Ly-49H on an NK cell and appears to preferentially express
Ly-49D and Ly-49H on NK cells that lack receptors for
Qa-1. Alternatively, regulation could be by inhibition of
Ly-49D expression on a Ly-49H2 cell, or inhibition of Ly-
49 activation molecules on cells expressing receptors for
Qa-1. One explanation for these findings is that the expres-
sion of the DAP-12 molecule may be regulated in NK
cells. Superimposed on this regulation, the expression of ei-
ther Ly-49D, Ly-49H, or both is obviously favored on a
DAP-121 NK cell, whereas lack of DAP-12 expression in
NK cells would presumably not permit Ly-49D and Ly-
49H expression. If this mechanism was operative in even a
fraction of NK cells, this might result in the skewing ob-
served here. Alternatively, the total number of DAP-12–
linked receptors on a given NK cell could be regulated
such that it is maintained within a narrow range. NK cells
might therefore have the potential to express a diverse rep-
ertoire of DAP-12–associated receptors, including Ly-49D,
Ly-49H, or CD94/NKG2C. Once a certain threshold of
DAP-12–mediated signaling was achieved during NK cell
ontogeny, further expression of activation receptors would
be turned off. This model would therefore predict that
Ly-49D1 or Ly-49H1 cells are more likely to express
additional DAP-12–associated receptors such as CD94/
NKG2C compared with Ly-49D1H1 NK cells. Many
other mechanisms are conceivable that could act at any of
several stages during NK cell ontogeny. Importantly, the
notable result is that a B6 NK cell that expresses one Ly-49
activation receptor is more likely to express a second Ly-49
activation receptor and less likely to express receptors for
the MHC class Ib Qa-1 molecule.
A recent report using single cell PCR to measure Ly-49
expression on individual NK cells reported that 16% of a
total of 62 NK cells analyzed expressed Ly-49H, and that
45% express Ly-49D (54). By contrast to the results re-
ported here, in which we find 56% Ly-49H1 NK cells and
57% Ly-49D1 NK cells in the spleen by flow cytometry,
the PCR analysis also found no positive association with
Ly-49D and Ly-49H on a single NK cell. One explanation
for this discrepancy is that RNA expression may not corre-
late directly with protein expression. Furthermore, deter-
mining the accuracy of single cell PCR detection of a
given RNA transcript is difficult due to sensitivity and
specificity issues. We conclude that while the single cell
PCR analysis of individual NK cells is a valuable contribu-
tion to our understanding of the total Ly-49 repertoire, the
flow cytometric analysis we present here is a more reliable
determination of Ly-49D and Ly-49H on splenic NK cells.
Ly-49 inhibitory receptors are currently thought to main-
tain tolerance to self by binding to MHC molecules and
preventing NK cell lysis (37). Expression of these inhibitory1352 Nonstochastic Coexpression of Activation Receptors on NK Cells
Ly-49 molecules in the mouse has previously been shown
to be detectable by flow cytometry 1–2 d after birth and to
increase to adult levels over the next 6–8 wk (40). Our ob-
servations that the Ly-49D and Ly-49H activation receptors
are expressed at approximately the same time during devel-
opment of NK1.11 cells but at a lower frequency suggest a
model in which a developing NK cell is more likely to ex-
press an inhibitory Ly-49 receptor before commencing ex-
pression of a Ly-49 activation receptor. However, we have
not yet determined whether each NK1.11 cell expressing
Ly-49D and/or Ly-49H also expresses a Ly-49 inhibitory
receptor. In addition, CD31 cells were not excluded from
this analysis, so it is possible that the NK1.11 populations
analyzed may also include rare splenic NK1.11 T lympho-
cytes expressing inhibitory Ly-49 molecules. Nevertheless,
our analysis of NK1.11 splenocytes suggests that expression
of Ly-49D and Ly-49H activation receptors initially lags be-
hind inhibitory receptor expression. Between days 30 and
50 postpartum, the expression of Ly-49D and Ly-49H by
splenic NK1.11 cells apparently increases at a somewhat
faster rate than the inhibitory receptors in this population,
resulting in larger subsets of NK1.11 cells expressing Ly-
49D or Ly-49H by day 50 than any one of the inhibitory
receptors. By this time, however, most NK cells express one
or another inhibitory receptor. Although further analysis of
single NK cells is necessary for detailed understanding, these
results are consistent with a model in which a developing
NK cell expresses a Ly-49 inhibitory receptor for self-MHC
to maintain tolerance before expressing a Ly-49 activation
receptor.
These considerations are also relevant to the missing-self
hypothesis. One prediction of this hypothesis is that NK
cells should not express activation receptors that could be
triggered by self-ligands in the absence of inhibitory self-
MHC–specific receptors. As we have observed here, this
prediction is applicable to developing NK cells, such that
developing NK cells gain the capacity to be inhibited by
self before they acquire the ability to be activated. Another
corollary is that if an activation receptor is expressed before
the inhibitory receptors, the activation receptor is unlikely
to be specific for self-molecules. As such, the NKR-P1C
(NK1.1) activation receptor may not be specific for self-
ligands. Therefore, as our detailed knowledge of NK cell
receptors grows, such considerations are necessary for a
complete understanding of the NK cell receptor repertoire.
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